-

01:40:24 PM

RLAY Stock News

RLAY - Relay Therapeutics Inc

09/18/23 4:05 PM

Nasdaq : RLAY

conferencesclinical trial

Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that data for RLY-4008

RHEA-AI

neutral

08/08/23 4:02 PM

Nasdaq : RLAY

earnings

Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights

Initiated dose expansion cohort for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Updated RLY-2608 600mg BID + fulvestrant data: interim clinical benefit rate of 86% (6 of 7 evaluable patients) & 1 of 5 patients with measurable disease achieved

RHEA-AI

neutral

08/01/23 4:05 PM

Nasdaq : RLAY

earnings

Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023

Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report second quarter 2023 financial results

RHEA-AI

neutral

05/25/23 5:01 PM

Nasdaq : RLAY

Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008

Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company

RHEA-AI

neutral

05/24/23 4:05 PM

Nasdaq : RLAY

conferences

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

Relay Therapeutics, Inc. (Nasdaq: RLAY) today announced that management will participate in two upcoming fireside chats: TD Cowen 4th Annual Oncology Innovation Summit, taking place virtually on Tuesday, May 30, 2023 at 1:00 p.m. ET Goldman Sachs

RHEA-AI

neutral

05/04/23 4:05 PM

Nasdaq : RLAY

earnings

Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights

Presented initial clinical data for RLY-2608 at American Association for Cancer Research (AACR) Annual Meeting 2023 Initiated clinical trial for RLY-5836, a chemically-distinct PI3Kα pan-mutant inhibitor $937.8 million in cash, cash equivalents and investments at end of Q1 2023, expected to fund

RHEA-AI

neutral

04/27/23 4:05 PM

Nasdaq : RLAY

earnings

Relay Therapeutics to Announce First Quarter 2023 Financial Results and Corporate Highlights

Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report first quarter 2023 financial

RHEA-AI

neutral

04/19/23 7:30 AM

Nasdaq : RLAY

conferences

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two upcoming fireside chats: Stifel 2023 Targeted Oncology Days, on Wednesday, April 26, 2023 at 12:30 p.m. ET BofA Securities 2023 Health Care Conference, on Tuesday, May

RHEA-AI

neutral

04/18/23 10:40 AM

Nasdaq : RLAY

clinical trial

Relay Therapeutics Announces Initial Clinical Data Demonstrating that RLY-2608 Selectively Targets Multiple PI3Kα Mutations

Multiple doses achieved sustained target exposure of ~80%+ mutant PI3Kα inhibition No Grade 3 hyperglycemia, rash or diarrhea observed at target exposures Favorable initial safety profile at target exposures Confirmed partial response in breast cancer patient with 12 prior lines of therapy Initial

RHEA-AI

neutral

03/06/23 7:30 AM

Nasdaq : RLAY

conferencesclinical trial

Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR

Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

RLAY Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websiterelaytx.com
Security nameRelay Therapeutics Inc
SectorManufacturing
Tags
- Health Technology
- Pharmaceuticals: Major
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
CountryUS

About Relay Therapeutics Inc

relay therapeutics is building the world’s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. by placing protein motion at the heart of drug discovery, relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. headquartered in cambridge, mass., relay therapeutics is a private company launched in 2016. to date, relay therapeutics has raised $120m in financing from third rock ventures, bvf partners, gv (formerly google ventures), an affiliate of d.e. shaw research, casdin capital, ecor1 capital, section 32 and alexandria venture investments. our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. if you're creative, collaborative and passionate